Drugs & Targets FDA approves neratinib for metastatic HER2-positive breast cancer February 28, 2020Vol.46 No.09
Drugs & Targets FDA accepts sNDA for Zejula in ovarian cancer indication February 28, 2020Vol.46 No.09
Drugs & Targets FDA grants RMAT designation to CD30 CAR-T Cell Therapy in hodgkin lymphoma indication February 28, 2020Vol.46 No.09
Drugs & Targets PMC report: FDA addressed rare diseases, expanded cancer treatment and targeted therapies in 2019 February 28, 2020Vol.46 No.09
Drugs & Targets Boehringer Ingelheim and Trutino Biosciences collaborate to grow cancer immunology portfolio with novel cytokine platform February 28, 2020Vol.46 No.09
Drugs & Targets FDA grants capmatinib priority review in NSCLC indication February 21, 2020Vol.46 No.08
Drugs & Targets FDA grants Breakthrough Therapy Designation for Astellas’ and Seattle Genetics’ agent Padcev in bladder cancer indication February 21, 2020Vol.46 No.08
Drugs & Targets FDA accepts Valoctocogene Roxaparvovec for Priority Review February 21, 2020Vol.46 No.08
Drugs & Targets FDA grants Priority Review for BMS agent lisocabtagene maraleucel February 14, 2020Vol.46 No.07
